BioXcel Therapeutics (NASDAQ:BTAI – Get Rating) had its target price reduced by HC Wainwright from $79.00 to $66.00 in a research report report published on Tuesday morning, The Fly reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for BioXcel Therapeutics’ Q1 2023 earnings at ($1.81) EPS, Q2 2023 […]